65,437 trials
Histologically or Cytologically Confirmed Pancreatic Ca · Unresectable or Borderline Resectable Pancreatic Ca
Primary: Number of Participants With Dose Limiting Toxicity (DLT ) — 0; 1; 0; 0 Participants
Obstetric Labor, Premature
Primary: Count of Patients With Recurrent Preterm Labor Within Two Weeks of Randomization — 2; 1 Participants — p=0.004
Amnestic Mild Cognitive Impairment · Alzheimer's Disease · Prodromal Alzheimer's Disease
Primary: Area Under the Concentration Versus Time Curve of MK-8931 From 0 to Infinity (AUC0-∞) — 3.48; 3.34 micromolar(µM)*hour(hr)
Epilepsy, Tonic-clonic
Primary: Percentage Participants With Treatment Emergent Adverse Events — 27.3 percentage of participants
Lung Neoplasm · Thoracic Surgery, Video-Assisted
Primary: Accuracy of Lung Nodule Localization — 9.6; 8.7 mm
Acute Myeloid Leukemia · Diffuse Large B-cell Lymphoma · Acute Lymphoblastic Leukemia
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Primary Sclerosing Cholangitis
Primary: Percentage Change From Baseline Through Week 24 in Serum Alkaline Phosphatase (ALP) — -4.5 percentage change in ALP
Chronic Lymphocytic Leukemia
Primary: Percentage of Participants With PD as Assessed by the Investigator Using Standard International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines or Death…
Hypertriglyceridemia
Primary: Efficacy of AZD0585 by Assessment of Percent Change in Serum Triglycerides — -15.57; -21.78; 11.15 % (percent change from baseline) — p=<0.0001
NUT Midline Carcinoma · Triple Negative Breast Cancer · Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation
Primary: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 — 4; 2; 0; 0 Participants
Sickle Cell Anemia · Sickle Cell Disease · Malaria
Primary: Number of Malaria Episodes — 5; 7 malaria episodes
Dysphagia · Pneumonia
Primary: Intra Hospital Mortality — 7; 0 Participants
Gastrointestinal Diseases
Primary: Maximal Measured Plasma Concentration (Cmax) of Rabeprazole — 393.50; 415.83 Nanograms per milliliter
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c (%) - Week 26 — 8.2; 8.1; -1.1; -1.1 % of HbA1c — p=<0.0001
Heart Failure
Primary: Difference in the DFT With an Azygos Vein Coil Versus the Standard SVC Coil. — 10.4; 12.2 Joules — p=0.103